New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder
Metabolism, San Francisco General Hospital, consultant to kinemed
study investigator. "We've long wanted to know the relationship be... rapidly demonstrate
human proof-of- concept in selected therapeutic areas. kinemed
acquiring and advancing drug candidates in indications for whic...
KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
... EMERYVILLE, Calif., Oct. 11 /PRNewswire/ -- kinemed
pathway-based drug discovery and developme..., Ph.D., Vice President, Research at
KineMed, "The kinemed
team set out to demonstrate regenerative capacity ...an
agent that can slow down this rate of turnover, kinemed
has shown in
preclinical studies that it can resto...
KineMed Presents Data Measuring Changes in Reverse Cholesterol
Transport for the First Time
RCT in real-time, in living animals. kinemed
also presented data
from its researchers and their...t
and reverse atherosclerosis, thereby positioning kinemed
leader in this field."
RCT is one of the many pathways for which kinemed
has the unique
technology and IP to measure in int...
KineMed to Present at the 4th Annual BIO Investor Forum
... EMERYVILLE, Calif., Oct. 8 /PRNewswire/ -- kinemed
Inc., a privately
held pathway-based drug discover...hat increase reverse cholesterol transport. About kinemed
KineMed, Inc. ("KineMed" or the "Company") is a d...nd diseases of inflammation and
is working to develop drugs both on its own and
KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
...ty in first-in-man studies. In the collaboration, kinemed
will identify new therapeutic utility in
in vivo p...rget is established for a selected
drug candidate, kinemed
and Merck KGaA will jointly determine the best
studied. Under the terms of the agreement, kinemed
will receive from Merck an
upfront payment, milest...